Genentech Announces Plans to Expand California Biologics Manufacturing Facilities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
today announced plans to invest more than $285 million for the expansion
of its biologics manufacturing facilities in Vacaville and Oceanside,
California. “This investment and expansion will result in the addition
of more than 250 new jobs at the Vacaville and Oceanside facilities over
the next four years, bringing the total number of Genentech
manufacturing jobs in California to close to 3,000,” said Ian Clark,
Chief Executive Officer of Genentech. The company currently employs
approximately 10,000 people in the state.

These investments in Genentech’s biologics manufacturing network will
enable the hiring of hundreds of skilled workers, ranging from
technicians to scientists and engineers. “California has always had an
impressive skilled workforce that has allowed Genentech to hire diverse
and talented individuals in various disciplines,” Clark said. “In recent
years California has made great strides toward improving the business
environment for life sciences innovation and incentivizing
manufacturing. We are committed to working with the state to continue
this positive progress and make California an even better place to grow
the industry.”

Genentech’s United States manufacturing network spans three locations in
California – South San Francisco, Vacaville, and Oceanside – and
Hillsboro, Oregon, producing medicines intended for the treatment of a
wide range of diseases including cancer, rheumatoid arthritis, and
asthma. When the expansion is complete, Genentech’s Vacaville facility
will not only be the largest producer of biologic medicines for the
Roche Group but also the largest biotech manufacturing facility in the
world.

Biologic medicines are large molecules that are created by biological
processes, rather than being chemically synthesized, and are typically
administered via injection or intravenously. Roche is a world leader in
biologic medicine manufacturing, with long-standing expertise in biotech
manufacturing and has the largest biotech production capacity of any
company worldwide.

The biologics unit at Roche consists of several manufacturing sites in
North America, Europe and Asia, which work as a closely aligned network
focused on all aspects of biologic medicine manufacturing and supply.
The manufacturing of biologic medicines consists of two operations, the
production of drug substance and drug product. The production of drug
substance uses genetically modified cells to serve as mini-factories
that can manufacture the appropriate proteins. The production of drug
product includes the final formulation of the medicine into a sterile
liquid or powder that can be filled into a vial, syringe or device,
which is then packaged for worldwide distribution.

Founded more than 35 years ago, Genentech is a leading biotechnology
company that discovers, develops, manufactures and commercializes
medicines to treat patients with serious or life-threatening medical
conditions. The company, a member of the Roche Group, has headquarters
in South San Francisco, California. For additional information about the
company, please visit http://www.gene.com.

GenentechRobin Snyder, 650-467-6800 (Media)Thomas Kudsk
Larsen, 650-467-2016 (Investors)Karl Mahler, 011 41 61 687 8503
(Investors)

Source: Genentech